Aicuris Receives FDA Priority Review for Pritelivir, Novel Herpes Treatment for Immunocompromised Patients

Key Takeaways

• FDA granted Priority Review for Aicuris’ pritelivir New Drug Application, accelerating review timeline with Q4 2026 PDUFA target date
• Pritelivir is a first-in-class helicase primase inhibitor showing superior lesion healing versus standard treatments in Phase 3 trials
• Drug specifically targets refractory herpes simplex virus infections in immunocompromised patients, addressing critical unmet medical need

---

FDA Accelerates Review of Breakthrough Herpes Treatment

The U.S. Food and Drug Administration has granted Priority Review designation to Aicuris Anti-infective Cures AG for their New Drug Application (NDA) of pritelivir, marking a significant milestone for immunocompromised patients suffering from treatment-resistant herpes simplex virus (HSV) infections.

Novel Mechanism Addresses Treatment-Resistant Infections

Pritelivir represents a paradigm shift in antiviral therapy as the first helicase primase inhibitor developed specifically for HSV treatment. Unlike traditional nucleoside analogs such as acyclovir and valacyclovir, pritelivir targets the viral helicase-primase complex, offering a new therapeutic approach for patients whose infections have developed resistance to standard treatments.

The Priority Review designation, reserved for drugs that offer significant improvements in treatment, reduces the FDA review timeline from 12 months to 8 months. The Prescription Drug User Fee Act (PDUFA) target date is set for Q4 2026, positioning pritelivir for potential market entry within the next two years.

Phase 3 Data Demonstrates Superior Efficacy

The NDA submission is supported by robust Phase 3 clinical trial data presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 conference. The pivotal studies demonstrated pritelivir’s superior complete lesion healing rates compared to investigator’s choice of standard antiviral therapy, while maintaining a favorable safety profile.

For immunocompromised patients—including those with HIV, organ transplant recipients, and cancer patients undergoing chemotherapy—resistant HSV infections pose serious health risks. Current treatment options become limited when standard antivirals fail, often requiring toxic alternatives like foscarnet with significant side effects.

Market Impact and Commercial Potential

The Priority Review designation signals FDA recognition of pritelivir’s potential to address a critical unmet medical need. While the target population of immunocompromised patients with refractory HSV represents a specialized market segment, the severity of these infections and limited treatment alternatives create significant commercial opportunity.

Aicuris’ novel mechanism of action could potentially expand beyond the initial indication if proven effective, with broader HSV populations representing substantial market potential. The company’s first-in-class status provides competitive advantages and potential pricing power in this therapeutic area.

Regulatory Pathway and Next Steps

The Priority Review process involves intensive FDA evaluation of pritelivir’s clinical data, manufacturing information, and proposed labeling. Aicuris will work closely with FDA reviewers to address any questions or requests for additional information during the review period.

Successful approval would make pritelivir the first new mechanism of action for HSV treatment in decades, potentially transforming care for patients with limited therapeutic options. The drug’s unique targeting of viral replication machinery offers hope for patients whose infections have exhausted conventional treatment approaches.

Investment and Industry Implications

The Priority Review designation represents a significant value inflection point for Aicuris, validating their innovative approach to antiviral drug development. Success with pritelivir could establish the company as a leader in novel antiviral therapeutics and potentially attract partnership opportunities with larger pharmaceutical companies.

The breakthrough also highlights the ongoing need for innovative approaches to viral resistance, a growing concern across infectious disease treatment as pathogens continue to evolve resistance mechanisms against existing therapies.

---

Frequently Asked Questions

What does Priority Review mean for pritelivir approval timeline?

Priority Review reduces FDA review time from 12 to 8 months, with a PDUFA target date in Q4 2026. This accelerated timeline reflects FDA recognition of pritelivir’s potential to address significant unmet medical need in treating resistant herpes infections.

How does pritelivir differ from existing herpes treatments?

Pritelivir is a first-in-class helicase primase inhibitor that targets viral replication machinery differently than standard treatments like acyclovir. This novel mechanism allows it to work against drug-resistant herpes strains that don’t respond to conventional nucleoside analog antivirals.

Who would be eligible for pritelivir treatment?

Pritelivir is being developed specifically for immunocompromised patients with refractory herpes simplex virus infections, including those with or without drug resistance. This includes HIV patients, organ transplant recipients, and cancer patients whose infections haven’t responded to standard antiviral therapy.